ArticleBone marrow transplantation2021
Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.
Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- D-VRD induction and autologous transplant in patients ≥70 years.Blood cancer journal · 2026Article
- Reduced dose versus standard melphalan conditioning for autologous stem cell transplantation in multiple myeloma: a single-center retrospective study.Annals of hematology · 2026Article
- The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.Haematologica · 2026Article
- Immuno-protective impact of Kangfuxin liquid on systematic toxicity associated with autologous hematopoietic stem cell transplantation in multiple myeloma.Frontiers in medicine · 2025Article
- Therapeutic Approaches to Increase the Survival Rate of Cancer Patients in the Younger and Older Population.Current aging science · 2024Review
- The obesity paradox in multiple myeloma: A report from Multiple Myeloma Research Foundation (MMRF) dataset.Cancer medicine · 2023Article
- Higher Age (≥60 Years) Increases the Risk for Adverse Events during Autologous Hematopoietic Stem Cell Transplantation.Cancers · 2023Article
- MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation.BMC cancer · 2023Article
- Autologous stem cell transplantation in an older adult population.Haematologica · 2022Article
- Applying stem cell therapy in intractable diseases: a narrative review of decades of progress and challenges.Stem cell investigation · 2022Review
- Review
- Article
- Review
- The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.Pharmaceuticals (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous stem cell transplantation (ASCT) has been used for treating multiple myeloma (MM) for over three decades and is generally reserved for patients younger than 65. Herein we report on outcomes of outpatient ASCT in a cohort of patients with MM aged ≥75 years. Between October 2005 and August 2020, 50 patients aged ≥75 years, received an ASCT at Mayo Clinic, Rochester. Median time from diagnosis to ASCT was 6.85 months (IQR 5.2-10.52) and 50%. received reduced intensity conditioning with melphalan 140 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.